Wednesday, February 4, 2009

Wedgewood Pharmacy Continues to Compound 17P Following FDA Rejection of New Drug Application by KV Pharmaceutical Co.

Feb 4, 2009 - Wedgewood Pharmacy will continue to compound 17-AlphaHydroxyprogesterone Caproate (17P) following the Federal Drug Administration's (FDA) January 26 rejection of KV Pharmaceutical Co.'s application to seek New Drug Approval for the substance.

The details can be read here.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)